Exploring the impact of first-line durvalumab plus chemotherapy on advanced biliary tract cancer: a systematic review and meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- The oncologist
- Publicado em
- 1 set 2025
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Exploring the impact of first-line durvalumab plus chemotherapy on advanced biliary tract cancer: a systematic review and meta-analysis
Patrick Reimann, Eva-Maria Schneider, Angela Djanani, Sylvia Mink, Thomas Winder, Magdalena Benda
Descritores MeSH
- Biliary Tract Neoplasms
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- Gemcitabine
- Cisplatin
- Deoxycytidine
- Humans
Veja também
Estudos relacionados
- First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer: A Systematic Review and Bayesian Network Meta-Analysis
- The real-world clinical effectiveness of durvalumab in advanced biliary tract cancer: a mimic comparative analysis through survival data reconstruction
- Durvalumab and pembrolizumab in advanced biliary tract cancer: a reconstructed patient-level mimic head-to-head comparative analysis
- First-line systemic therapy and sequencing options in advanced biliary tract cancer: A systematic review and network meta-analysis